VAY736

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

1

Fludara

Sanofi

Phase 3

12

Tuoyi

SSun Yat-sen University

Phase 3

43

Busulfex

Akero Therapeutics

Phase 3

34

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

15

Alka-Seltzer

AAbbott

Phase 3

16

Oxycontin

PPurdue Pharma LP

Phase 3

17

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

48

Mitomycin C

GGynecologic Oncology Group

Phase 3

29

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

110

Tpoxx

SSIGA Technologies

Phase 3

1Show 38 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Primary Sjögren's Syndrome2 trials

PD of VAY736 in Patients With Primary Sjögren's Syndrome

Completed·Novartis·Phase 2·NCT02149420·27 enrolled

Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome

Withdrawn·Novartis·Phase 1/2·NCT02495129

Efficacy and Safety2 trials

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting·Novartis·Phase 3·NCT05349214·506 enrolled

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Completed·Novartis·Phase 2·NCT03656562·107 enrolled

Relapsing-Remitting Multiple Sclerosis1 trial

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

Terminated·Novartis·Phase 2·NCT02038049·8 enrolled

B-Cell1 trial

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

Completed·Novartis·Phase 2/3·NCT03217422·68 enrolled

Lymphoma1 trial

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Terminated·Novartis·Phase 1·NCT04903197·18 enrolled

10 more indications

Pemphigus Vulgaris1 trial

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

Terminated·Novartis·Phase 2·NCT01930175·13 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Terminated·Novartis·Phase 2·NCT03287414·30 enrolled

Rheumatoid Arthritis1 trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients

Completed·Novartis·Phase 1·NCT02675803·65 enrolled

CLL1 trial

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Terminated·Novartis·Phase 1·NCT03400176·39 enrolled

Primary Sjogren's Syndrome1 trial

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Completed·Novartis·Phase 2·NCT02962895·190 enrolled

Relapsed or Refractory1 trial

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

Terminated·Novartis·Phase 1·NCT02137889·3 enrolled

Hidradenitis Suppurativa1 trial

A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa

Completed·Novartis·Phase 2·NCT03827798·248 enrolled

Sjögrens Disease1 trial

A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Active, not recruiting·Novartis·Phase 2·NCT06293365·155 enrolled

Sjögren´s Disease1 trial

A Randomized, Double-blind, Placebo-controlled, 2-arm Multicenter Phase III Study to Assess the Efficacy and Safety of Ianalumab in Participants With Sjogren's Disease With High Symptom Burden (THALASSA)

Recruiting·Novartis·Phase 3·NCT07621809·570 enrolled

Sjogren syndrome1 trial

A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1)

Completed·Novartis·Phase 3·NCT05350072·275 enrolled

Details

Drug Info

Related News